Diagnostic pitfalls in [68Ga]Ga-DOTATATE PET/CT imaging: a systematic review.

Abstract

[68Ga]Ga-DOTA-Tyr3-octreotate ([68Ga]Ga-DOTATATE) is an established somatostatin receptor imaging agent that has demonstrated superior efficacy in visualizing neuroendocrine tumors (NETs) and meningiomas compared with traditional [111In]In-octreotide imaging. Despite its enhanced affinity and sensitivity, [68Ga]Ga-DOTATATE imaging is not without challenges. To date, numerous diagnostic pitfalls and false-positive findings have been reported. This systematic review investigates the currently recognized diagnostic pitfalls in [68Ga]Ga-DOTATATE positron imaging. A systematic literature search was conducted using PubMed, Scopus, and Web of Science databases, with the most recent update on 8 March 2024. Two authors screened the titles and abstracts of retrieved articles and selected studies based on predefined inclusion and exclusion criteria. Qualitative analysis of 70 included research articles, encompassing 199 patients, identified 234 diagnostic pitfalls. Malignant neoplastic etiologies predominated, constituting 56% of pitfalls, followed by nononcologic pitfalls (32.1%), and benign oncologic tumors (11.9%). Anatomically, the head and neck region was the most frequent site for pitfalls (35.5%), followed by the musculoskeletal system (27.4%), abdomen (17.5%), and chest (16.6%). Pelvic-related pitfalls were least common, accounting for only 3% of cases. This study details potential diagnostic pitfalls, predominantly occurring in the head-neck regions - primary sites for meningiomas and paragangliomas. Understanding these diagnostic pitfalls is crucial for accurate diagnosis. Moreover, recognizing these diagnostic pitfalls may lead to novel applications of [68Ga]Ga-DOTATATE beyond its conventional use in NETs and meningiomas, potentially expanding its diagnostic utility.